Despite meeting the primary endpoint in a Phase III study, two patients treated with Merck and Daiichi Sankyo’s experimental ...
Initial results from dose escalation in the first in-human phase 1 trial of DS-9606 suggest early promising clinical activity in patients with advanced solid tumours known to express Claudin-6 (CLDN6) ...
TOKYO, Japan & BASKING RIDGE, NJ, USA I 15, 2024 I Initial results from dose escalation in the first-in-human phase 1 trial of DS-9606 suggest ...